ResMed (RMD)
(Delayed Data from NYSE)
$209.34 USD
+3.38 (1.64%)
Updated May 30, 2024 04:00 PM ET
After-Market: $209.34 0.00 (0.00%) 6:26 PM ET
1-Strong Buy of 5 1
C Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$209.34 USD
+3.38 (1.64%)
Updated May 30, 2024 04:00 PM ET
After-Market: $209.34 0.00 (0.00%) 6:26 PM ET
1-Strong Buy of 5 1
C Value B Growth D Momentum C VGM
Zacks News
ResMed (RMD) Q3 Earnings & Sales Beat on Overall Growth
by Zacks Equity Research
ResMed (RMD) beats earnings and sales in Q3 on solid contributions from domestic and international businesses.
Integra LifeSciences (IART) Tops on Q1 Earnings, '18 View Up
by Zacks Equity Research
Integra LifeSciences' (IART) revenue growth was primarily driven by high organic revenues, successful progress with Codman integration and progress with the channel expansion strategy.
LabCorp (LH) Beats on Q1 Earnings, Revenues, Lifts '18 View
by Zacks Equity Research
LabCorp's (LH) Diagnostics business was solid on the back of increasing acquisitions, organic volume expansion and a favorable foreign exchange scenario.
Thermo Fisher (TMO) Q1 Earnings Beat Estimates, '18 View Up
by Zacks Equity Research
Thermo Fisher's (TMO) performance in Q1 benefits from a series of product launches alongside a major progress in precision medicine initiatives.
Illumina (ILMN) Beats on Q1 Earnings, Lifts '18 Guidance
by Zacks Equity Research
Illumina's (ILMN) collaboration with Bristol-Myers Squibb and Loxo Oncology are likely to yield results in the near term.
Edwards Lifesciences (EW) Q1 Earnings Beat, Revenues Miss
by Zacks Equity Research
Edwards Lifesciences (EW) gains from THVT strength on continued therapy adoption across all geographies in Q1.
Medical Product Stock Earnings Roster for Apr 26: BAX & More
by Zacks Equity Research
Let's take a look at the factors that are likely to impact the earnings results of a few MedTech bigwigs within the broader Medical universe.
Boston Scientific (BSX) Beats on Q1 Earnings, Lifts '18 View
by Zacks Equity Research
Boston Scientific (BSX) registers steady growth across all business lines and geographies in Q1.
Can ResMed (RMD) Repeat Stable Device Growth in Q3 Earnings?
by Zacks Equity Research
ResMed's (RMD) sleep apnea patient volume consistently witnesses a steady expansion. We expect this upside to continue in the fiscal third quarter as well.
Global Expansion and Product Launches to Aid ResMed's Growth
by Zacks Equity Research
ResMed (RMD) continues to benefit from solid sales of sleep devices, respiratory care devices, mask systems and software solutions globally.
Here's Why You Must Add ResMed (RMD) to Your Portfolio Now
by Zacks Equity Research
ResMed (RMD) boosts investor confidence on strength in Software-as-a-Service businesses as well as new mask products and devices.
ResMed (RMD) Rides High on Robust Global Growth & Innovation
by Zacks Equity Research
ResMed (RMD) consistently invests and expands globally in high-growth markets like China, South Korea, India, Brazil and across the Eastern Europe belt.
Why Is ResMed (RMD) Down 7.5% Since the Last Earnings Report?
by Zacks Equity Research
ResMed (RMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Haemonetics' (HAE) Q3 Earnings Top Estimates, EPS View Up
by Zacks Equity Research
Continued momentum in new business generation and geographical expansions drive Haemonetics (HAE) in the third quarter.
LabCorp (LH) Q4 Earnings Beat Estimates, '18 View Promising
by Zacks Equity Research
LabCorp's (LH) Covance Drug Development of late begins to gain traction from Chiltern acquisition, strong organic growth and a favorable foreign currency translation.
Align Technology Banks on Global Growth, Competition Rife
by Zacks Equity Research
We are encouraged by Align Technology's (ALGN) solid Invisalign Technology prospects and growth in North America and internationally, particularly in Asia Pacific.
Genomic Health (GHDX) Oncotype DX GPS Test Results Positive
by Zacks Equity Research
Genomic Health's (GHDX) efforts to improve its prostate cancer business are encouraging.
IDEXX Laboratories Strong on CAG Business Amid Currency Woes
by Zacks Equity Research
IDEXX's (IDXX) innovation-based global strategy is leading to growth at CAG Diagnostics.
Hill-Rom (HRC) Trades on Product Innovation, Competition Rife
by Zacks Equity Research
Hill-Rom (HRC) focuses on product innovation, the latest launch being Connex Cardio ECG.
Integra LifeSciences Global Prospects Solid, Competition Rife
by Zacks Equity Research
Integra LifeSciences (IART) witnesses strong global sales within specialty surgical driven by strength in door repair and tissue ablation franchises in Asia Pacific and Europe.
Edwards Lifesciences (EW) Beats on Q4 Earnings and Revenues
by Zacks Equity Research
Edwards Lifesciences (EW) gains from strength in THVT on continued therapy adoption across all geographies in Q4.
Illumina (ILMN) Tops Q4 Earnings & Revenues, Issues Guidance
by Zacks Equity Research
Illumina (ILMN) gains from strength in sequencing consumables and instruments as well as microarray portfolios in Q4.
Align Technology (ALGN) Q4 Earnings Top on Invisalign Sales
by Zacks Equity Research
Align Technology (ALGN) gains on solid contributions from the Clear Aligner as well as Scanner and Service segments in Q4.
Zimmer Biomet (ZBH) Q4 Earnings Meet Estimates, Sales Beat (Revised)
by Zacks Equity Research
Zimmer Biomet (ZBH) rides high on Hip and S.E.T segments in Q4.
Abaxis (ABAX) at a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Abaxis (ABAX) rides high on recently received approval from USDA.